Evaluating the results of chronic hepatitis B treatment with Tenofovir Disoproxil Fumarate (TDF) at Phu Tho Provincial General Hospital. Methods: Study design: Cross-sectional study. Sample size: There were 250 chronic hepatitis B patients receiving daily TDF treatment from 9/2021- 09/2023. Results: Medium age: 51,08 ± 16,14, Males take 60%. Ater 3 months and 6 months of treatment: 40/250 patients still had functional symptoms and no physical symptoms; percentage of patients had ALT ≥ 40 U/l were 22% and 12% respectively; percentage of patients reduced HBV-DNA ≥ 1log were 92% and 98% respectively; percentage of patients with HbsAg(+) were 86,4% và 64,4% respectively; The rate of liver fibrosis response at 6 months was 15.2%. Conclusion: TDF is an effective treatment for chronic hepatitis B and improves liver fibrosis.